With four STEP* studies published on the profound impact that semaglutide 2.4 mg confers on weight loss, these indicate GLP-1 signalling as a powerful and effective target for obesity therapy and thus, usher in a new era for obesity care, said a leading expert during the ADA 2021 session.
A once-weekly dosing of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide for type 2 diabetes (T2D) passes muster in real world, conferring benefits for blood sugar and weight across adult patients with varying characteristics and background medication, according to the Denmark (DK)/Sweden (SE) data from the SURE programme.
In individuals with radio-iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) who have progressed during/after prior VEGFR-targeted therapy, the VEGFR2/MET/AXL/RET inhibitor cabozantinib showed a significant progression-free survival (PFS) benefit, according to findings of the phase III COSMIC-311 trial presented at ASCO 2021.
Nonalcoholic fatty liver disease (NAFLD) patients with morbid obesity who undergo bariatric surgery are less likely to develop cancer than their peers who did not go through the procedure, as shown in a study.
Individuals who do resistance exercise (RE) have a significantly lower risk of developing obesity regardless of whether one meets the aerobic exercise (AE) guidelines, suggests a study. However, those who meet both the RE and AE guidelines show the lowest risk of obesity.
The increasing use of social media and online reviews has made it easier for patients to comment publicly—on Facebook and Google reviews, for instance—on the care they receive. Positive comments are heartening for any healthcare professional to read.
A culturally contextualized smartphone-based lifestyle intervention helps Asian adults with type 2 diabetes (T2D) shed excess pounds and improve glycaemic outcomes, according to data from the D’LITE* study.